• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Ventura MT Casciaro M Gangemi S Buquicchio R Immunosenescenc


    [10] Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune 56985-40-1 depletion and cytokines up-regulation. Clin Mol Allergy 2017;15:21. [11] Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriatr Oncol 2014;5(2):204–18.
    [12] Lin Y, Kim J, Metter EJ, Nguyen H, Truong T, Lustig A, et al. Changes in blood lympho-cyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors. Immun Age 2016;13:24. [13] Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. J Am Geriatr Soc 2007;55(6):864–71. [14] Puzianowska-Kuznicka M, Owczarz M, Wieczorowska-Tobis K, Nadrowski P, Chudek J, Slusarczyk P, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Age 2016;13:21. [15] Van Epps P, Oswald D, Higgins PA, Hornick TR, Aung H, Banks RE, et al. Frailty has a stronger association with inflammation than age in older veterans. Immun Age 2016;13:27.
    [19] Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology 2016;5(5): e1093722.
    [20] Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differ-ential expression of cytokines in breast cancer patients receiving different chemo-therapies: implications for cognitive impairment research. Support Care Cancer 2012;20(4):831–9.
    [23] Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C, et al. Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dys-function? Brain Behav Immun 2013;30:S99–108 Suppl.
    [24] Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer sur-vivors. Brain Behav Immun 2013;30:S109–16 Suppl.
    [25] Janelsins Michelle C, Heckler Charles E, Peppone Luke J, Ahles Tim A, Mohile Supriya G, Mustian Karen M, Palesh Oxana, O’Mara Ann M, Minasian Lori M, Williams Annalynn M, Magnuson Allison, Geer Jodi, Dakhil Shaker R, Hopkins Judith O, Morrow Gary R. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. J Clin Oncol 2018;36(32): 3231–9.
    [26] Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, et al. Cog-nitive complaints in survivors of breast Cancer after chemotherapy compared with age-matched controls: an analysis from a Nationwide, multicenter, prospective lon-gitudinal study. J Clin Oncol 2017;35(5):506–14.
    [27] Karnofsky DABJ. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949.
    [34] Bennet J, Winters-Stone KM, Dobek J, Nail LM. Frailty in older breast cancer survivors: age, prevalence, and associated factors. Oncol Nurs Forum 2013: E126–34.
    [35] Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses 2006;67:212–5. [36] Yuan Y, Vora N, Sun CL, Li D, Smith D, Mortimer J, et al. Association of pre-chemo-therapy peripheral blood pro-inflammatory and coagulation factors with physical function in women with breast cancer. Oncologist 2017;22(10):1189–96. [37] Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, et al. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget 2016;7(21):29977–88.
    [38] Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, et al. functional decline and resilience in older women receiving adjuvant chemotherapy for breast Cancer. J Am Geriatr Soc 2018. [39] Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, et al. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers 2010;25(3):126–35.
    [40] Tripsianis G, Papadopoulou E, Anagnostopoulos K, Botaitis S, Katotomichelakis M, Romanidis K, et al. Coexpression of IL-6 and TNF-alpha: prognostic significance on breast cancer outcome. Neoplasma 2014;61(2):205–12. [41] Tripsianis G, Papadopoulou E, Romanidis K, Katotomichelakis M, Anagnostopoulos K, Kontomanolis E, et al. Overall survival and clinicopathological characteristics of pa-tients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-alpha and TGF-beta1. Asian Pac J Cancer Prev 2013;14(11):6813–20.